Monday, September 23, 2019 - 07:00
  • Preliminary results of IPH5401 STELLAR-001, a dose escalation Phase I study in patients with advanced solid tumors
  • 1-year survival data of monalizumab in combination with cetuximab in head and neck cancer patients
  • Preliminary safety results of monalizumab in combination with durvalumab and standard of care in first-line colorectal cancer

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) will provide an update on its clinical trial pipeline at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, September 27-October 1, 2019.  Highlights will include preliminary results of STELLAR-001, a Phase I dose escalation study of the anti-C5aR antibody, IPH5401, in combination with durvalumab in advanced solid tumors. In addition, updated data from ongoing clinical trials evaluating lead asset, monalizumab, partnered with AstraZeneca, will be presented.

“We are very pleased to present new data on two of our clinical assets at ESMO Congress 2019. Our poster on IPH5401 will be the first clinical data presentation for this agent in combination with an anti-PD-L1 antibody in oncology,” commented Pierre Dodion, Chief Medical Officer of Innate Pharma. We will also present late follow-up clinical data on the combination of monalizumab and cetuximab in head and neck cancer. We look forward to sharing this new, promising clinical data to the medical community.”

Poster presentations September 30, 2019, 12:00-13:00 - Poster Area Hall 4

  • Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors. (ID 1285)
    Poster #1203P | Presenter: Christophe Massard (Villejuif, France)
  • Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data. (ID 1242)
    Poster #1134P | Presenter: Roger B. Cohen (Philadelphia, PA, USA)
  • Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC) (ID 3681)
    Poster #1201P | Presenter: May Cho (Sacramento, CA, USA)
AttachmentSize
PR in English104.54 KB
CP en français80.62 KB